P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

Pharmacokinetics Clinical Trial

— DIPLOID  

Official title:

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04489134
• Other study ID #: 35RC19_8877_DIPLOID
• Status: Recruiting
• Phase: Phase 2
• Start date: February 15, 2022
• Est. completion date: February 15, 2024

Study information

• Verified date: March 2022
• Source: Rennes University Hospital
• Contact: Marie LE NAOU
• Phone: 299282555
• Email: marie.lenaou[@]chu-rennes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tacrolimus is a drug administered orally available with different formulations: immediate release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named LCP-Tacro (Envarsus®), formulated using the Melt-Dose process. Tacrolimus is a lipophilic macrolide drug able to passive transmembrane diffusion. Its bioavailability displays a large interindividual variability, from 9 to 43%. Indeed, tacrolimus is a substrate of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4). P-gp is an efflux protein mainly located at the apex of the epithelia of the intestine, lymphocyte, kidney and blood-brain barrier. P-gp therefore limits the intestinal resorption of tacrolimus and also its diffusion into its target compartment (i.e the lymphocyte. The expression of this protein is different throughout the digestive tract with maximum expression at the ileal level. CYP3A4 is a coenzyme that is responsible of more than 90% of the metabolism of tacrolimus, at the digestive and hepatic level. Both P-gp and CYP3A4 play a role in tacrolimus absorption/diffusion process. A new formulation of tacrolimus, LCP-Tacro, (Envarsus®) was approved in 2014. Its efficacy was compared to Prograf® in two phase III de novo or switch Prograf® trials in kidney transplantation. With tacrolimus, there is a strong inter-individual pharmacokinetic variability which, to date, has not been fully characterized. Variations in bioavailability may partly explain this high variability. The different formulations are resorbed at distinct gastrointestinal sites which could explain different absorptions between Prograf/Advagraf and LCP-Tacro forms. These findings raise the question of the role of P-gp in explaining the difference in bioavailability between formulations. The use of a P-gp inhibitor could therefore have a different impact on exposure to different galenic formulations. Verapamil is an inhibitor of P-gp and CYP 3A4, which is frequently prescribed and recommended by FDA for drug-drug interaction studies aiming at evaluating P-gp substrates, used in healthy volunteers at dosages up to 240 mg/D13-14. Otherwise, verapamil-tacrolimus interaction has been characterized in vitro. It has also been shown that inhibitory effect of verapamil at a single dose of 120 mg administered one hour prior to the administration of a P-gp substrate exhibited an optimum power of inhibition. The safety of Advagraf® and Envarsus® administrations have already been subjected to several phase I trials in healthy volunteers reinforcing the knowledge of their safety profile. The aim of the study is to compare the interaction profile of Advagraf® and Envarsus® when co-administered with verapamil in healthy subjects and to provide guidelines on tacrolimus dosage adjustment in such cases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: February 15, 2024
• Est. primary completion date: February 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adults (> 18 years)
• Non smokers (for at least 6 months)
• Biological parameters within normal range (blood count, urea, creatinine, AST, ALT, GGT, bilirubine)
• BMI within 18 and 25
• Vaccinated against Covid 19
• Negative urinary and plasma pregnancy test
• Having effective contraception for the duration of the study and for 10 days after the last administration of the study treatment (for women and men of childbearing potential)
• Informed consent

Exclusion Criteria:

• participation to another study with incompatible procedure regarding the French law on research
• Treatment with a drug drug interaction with tacrolimus
• Cardiac rhythm at rest below 50 bpm
• Cardiac issue detected on electrocardiogram
• Cancer or history of cancer
• Chronic infection or history of chronic infection
• Diabetes or history of diabetes
• Hypertension or history of hypertension
• Pregnancy or lactation
• Deprived of liberty (curatorship, guardianship or incarcerate)

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• Treatment A
Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
• Treatment B
Administration of a 2 mg dose of LCP-tacro (Envarsus®)
• Treament C
Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
• Treatment D
Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)

Biological:
• Pharmacocinetik
Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.

Genetic:
• Genetic
A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.

Other:
• Selection visit:
During this visit, it will be asked to sign the following consent and it will be carried out: a clinical examination (questioning and physical examination with measurement of height and weight); a blood test (18 mL); a blood pregnancy test if you are a woman; a cardiac assessment (electrocardiogram). These results should be normal.

Locations

Country	Name	City	State
France	CHU de Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve	Change in area under the curve of tacrolimus blood concentrations between 0 and 24h.	Between 0 and 24 hours
Secondary	Cmax	Blood pharmacokinetic parameters: peak concentration (Cmax)	Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours
Secondary	Trough concentration	Blood pharmacokinetic parameters: trough concentration (Cmin)	24 hours
Secondary	Apparent clearance	Blood pharmacokinetic parameters: apparent clearance (Cl/F)	0-24 hours
Secondary	Half-life	Blood pharmacokinetic parameters: half-life (T1/2)).	0-24 hours
Secondary	AUC	Intracellular pharmacokinetic parameters: AUC	0-24 hours
Secondary	Cmax	Intracellular pharmacokinetic parameters: Cmax	Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours
Secondary	Cmin	Intracellular pharmacokinetic parameters:Cmin	24 hours
Secondary	CI/F	Intracellular pharmacokinetic parameters: Cl/F	0-24 hours
Secondary	T1/2	Intracellular pharmacokinetic parameters:T1/2	0-24 hours
Secondary	ABCB1 genotypes	ABCB1 genotypes	Day 0
Secondary	Others genotypes	Other genotypes of interest coding for metabolism (CYP3A4, CYP3A5…) or drug transport (CNT3…).	Day 0